[해외논문]
Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18)
Genes, chromosomes & cancer ,
v.30 no.4 ,
2001년, pp.375 - 382
Horsman, Douglas E.
(Division of Pathology and Laboratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada)
,
Connors, Joseph M.
(Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada)
,
Pantzar, Tapio
(Division of Pathology and Laboratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada)
,
Gascoyne, Randy D.
(Division of Pathology and Laboratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada)
Follicular lymphoma is characterized by the t(14;18) in up to 85% of cases. Almost all cases display evidence of secondary chromosomal alterations at initial diagnosis. The influence of recurrent secondary changes on disease progression has not been fully determined. The purpose of this study was to...
Follicular lymphoma is characterized by the t(14;18) in up to 85% of cases. Almost all cases display evidence of secondary chromosomal alterations at initial diagnosis. The influence of recurrent secondary changes on disease progression has not been fully determined. The purpose of this study was to define the full spectrum of recurrent karyotypic events present at diagnosis in a large cohort of cases and to evaluate the sequence of cytogenetic evolution in relation to morphologic progression. A total of 165 cases of follicular lymphoma with t(14;18) were ascertained for which complete clinical information, histopathology, immunophenotype, and karyotype were available. One hundred sixty cases showed secondary alterations with an average of 7.9 additional changes per case. Recurrent alterations seen at the 10% or greater level included +X, +1q21–q44, +7, +12q, +18q, del(1)(p36), del(6q), del(10)(q22–q24), the development of polyploidy and sidelines, and the presence of extra marker chromosomes and chromosomal additions. Changes that correlated with morphologic progression included del(1)(p36), del(6q), del(10)(q22–q24), +7, the total number of abnormalities, the number of markers and additions, and the presence of polyploidy. The most frequent second event arising after the t(14;18) was duplication of the der(18)t(14;18). This study demonstrates that the number and type of secondary chromosomal alterations in follicular lymphoma is highly variable between cases, but that a relatively small number of changes are seen repeatedly in different combinations. A consistent pattern of cytogenetic evolution could not be identified. Potentially significant gene duplications or amplifications may be disguised within marker chromosomes and additions. Additional cytogenetic investigation is required to decipher the karyotypic complexity associated with the progression of follicular lymphoma. © 2001 Wiley-Liss, Inc.
Follicular lymphoma is characterized by the t(14;18) in up to 85% of cases. Almost all cases display evidence of secondary chromosomal alterations at initial diagnosis. The influence of recurrent secondary changes on disease progression has not been fully determined. The purpose of this study was to define the full spectrum of recurrent karyotypic events present at diagnosis in a large cohort of cases and to evaluate the sequence of cytogenetic evolution in relation to morphologic progression. A total of 165 cases of follicular lymphoma with t(14;18) were ascertained for which complete clinical information, histopathology, immunophenotype, and karyotype were available. One hundred sixty cases showed secondary alterations with an average of 7.9 additional changes per case. Recurrent alterations seen at the 10% or greater level included +X, +1q21–q44, +7, +12q, +18q, del(1)(p36), del(6q), del(10)(q22–q24), the development of polyploidy and sidelines, and the presence of extra marker chromosomes and chromosomal additions. Changes that correlated with morphologic progression included del(1)(p36), del(6q), del(10)(q22–q24), +7, the total number of abnormalities, the number of markers and additions, and the presence of polyploidy. The most frequent second event arising after the t(14;18) was duplication of the der(18)t(14;18). This study demonstrates that the number and type of secondary chromosomal alterations in follicular lymphoma is highly variable between cases, but that a relatively small number of changes are seen repeatedly in different combinations. A consistent pattern of cytogenetic evolution could not be identified. Potentially significant gene duplications or amplifications may be disguised within marker chromosomes and additions. Additional cytogenetic investigation is required to decipher the karyotypic complexity associated with the progression of follicular lymphoma. © 2001 Wiley-Liss, Inc.
참고문헌 (36)
Cancer Genet Cytogenet Arranz 87 1 1996 10.1016/0165-4608(95)00230-8
J Clin Oncol Bastion 15 1587 1997 10.1200/JCO.1997.15.4.1587
Blood Bentz 88 1437 1996 10.1182/blood.V88.4.1437.bloodjournal8841437
Genes Chromosomes Cancer Dreyling 22 72 1998 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.0.CO;2-K
Blood Elenitoba-Johnson 91 4677 1998 10.1182/blood.V91.12.4677
Mod Pathol Gascoyne 10 731 1997
Cancer Greiner 75 370 1995 10.1002/1097-0142(19950101)75:1+<370::AID-CNCR2820751319>3.0.CO;2-Q
Blood Guan 88 1418 1996 10.1182/blood.V88.4.1418.bloodjournal8841418
J Clin Oncol Harris 17 3835 1999 10.1200/JCO.1999.17.12.3835
Nature Hockenbery 348 334 1990 10.1038/348334a0
Blood Horning 83 881 1994 10.1182/blood.V83.4.881.881
Am J Clin Pathol Horsman 103 472 1995 10.1093/ajcp/103.4.472
An International System for Human Cytogenetic Nomenclature Mitelman 1995 ISCN. 1995. An International System for Human Cytogenetic Nomenclature. ed. Basel: Karger.
Leuk Lymphoma James 28 383 1998 10.3109/10428199809092694
Blood Johansson 86 3905 1995 10.1182/blood.V86.10.3905.bloodjournal86103905
Leuk Lymphoma Karsan 10 433 1993 10.3109/10428199309148200
Cancer Surveys Knutsen 30 163 1997
Blood Lo Coco 82 2289 1993 10.1182/blood.V82.8.2289.2289
Hematol Oncol Mann 1 187 1983 10.1002/hon.2900010209
Nature McDonnell 349 254 1991 10.1038/349254a0
2000 Mitelman Database of Catalogue of Chromosome Aberrations in Cancer. 2000. Mitelman F, Johansson B, Mertens F, eds. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
Blood Monni 90 1168 1997 10.1182/blood.V90.3.1168
Blood 89 3909 1997 10.1182/blood.V89.11.3909
Cancer 49 2112 1982 10.1002/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2
Science Nowell 194 23 1976 10.1126/science.959840
Br J Haematol Rohatiner 79 349 1991 10.1111/j.1365-2141.1991.tb08039.x
Blood Sander 82 1994 1993 10.1182/blood.V82.7.1994.1994
Genes Chromosomes Cancer Simon 28 106 2000 10.1002/(SICI)1098-2264(200005)28:1<106::AID-GCC13>3.0.CO;2-S
Blood Tilly 84 1043 1994 10.1182/blood.V84.4.1043.1043
Am J Pathol Villuendas 153 887 1998 10.1016/S0002-9440(10)65630-1
N Engl J Med Vogelstein 319 525 1988 10.1056/NEJM198809013190901
Blood Whang-Peng 85 203 1995 10.1182/blood.V85.1.203.bloodjournal851203
Blood Yano 80 758 1992 10.1182/blood.V80.3.758.758
J Clin Oncol Yuen 13 1726 1995 10.1200/JCO.1995.13.7.1726
N Engl J Med Yunis 316 79 1987 10.1056/NEJM198701083160204
Cancer Genet Cytogenet Zattara-Cannoni 107 98 1998 10.1016/S0165-4608(98)00095-8
더보기
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.